4-Nov-2024 6:01 AM CST - Business Wire Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precisions jou
29-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Report Third Quarter Results on November 4, 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (D
28-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. The event will feature Key Opinion Leaders in the field of Hepat
21-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format: Panel Guggenheim Inaugural Healthcare Conference Date
4-Nov-2024 6:01 AM CST - Business Wire Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precisions jou
29-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Report Third Quarter Results on November 4, 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (D
28-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. The event will feature Key Opinion Leaders in the field of Hepat
21-Oct-2024 6:01 AM CST - Business Wire Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format: Panel Guggenheim Inaugural Healthcare Conference Date